During the past decade, Flevoziekenhuis conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 2 clinical trials were completed, i.e. on average, 4.9% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 1 clinical trials were completed. i.e. 6.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Flevoziekenhuis" #1 sponsor was "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 15 trials, followed by "Maastricht University Medical Center" with 5 trials sponsored, "Amsterdam UMC, location VUmc" with 4 trials sponsored, "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 4 trials sponsored and "Bayer" with 4 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Flevoziekenhuis" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 11 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 6 trials as a collaborator, "Flevoziekenhuis" with 6 trials as a collaborator, "Amsterdam UMC, location VUmc" with 4 trials as a collaborator and "Borstkanker Onderzoek Groep" with 4 trials as a collaborator. Other collaborators include 97 different institutions and companies that were collaborators in the rest 85 trials.

According to Clinical.Site data, the most researched conditions in "Flevoziekenhuis" are "Colorectal Cancer" (4 trials), "Appendicitis" (3 trials), "Breast Neoplasms" (2 trials), "Kidney Failure, Chronic" (2 trials) and "Neoplasms" (2 trials). Many other conditions were trialed in "Flevoziekenhuis" in a lesser frequency.

Most popular intervention types in "Flevoziekenhuis" are "Drug" (25 trials), "Procedure" (14 trials), "Other" (12 trials), "Device" (6 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Appendectomy" (2 trials), "1 or 2 cycle(s) HDM (High Dose Melphalan)" (1 trials), "2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)" (1 trials) and "AT1 blocker candesartan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Flevoziekenhuis" are 44 trials for "All" genders, 13 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Flevoziekenhuis". undefined are not yet recruiting, 18 are recruiting, 11 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 13 completed trials in Flevoziekenhuis, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Flevoziekenhuis, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 21 trials that are defined as “Not Applicable".